Modulation	O
of	O
angiogenesis	O
and	O
progelatinase	O
a	O
by	O
thrombin	O
receptor	O
mimetics	O
and	O
antagonists	O
.	O

The	O
angiogenic	O
action	O
of	O
thrombin	O
has	O
been	O
shown	O
to	O
be	O
mediated	O
by	O
activation	O
of	O
the	O
thrombin	O
receptor	O
.	O

In	O
this	O
report	O
we	O
studied	O
the	O
effects	O
of	O
SFLLR	O
,	O
an	O
agonist	O
of	O
the	O
activated	O
thrombin	O
receptor	O
and	O
thrombin	O
receptor	O
peptide	O
and	O
non	O
peptide	O
antagonists	O
on	O
angiogenesis	O
in	O
the	O
chick	O
chorioallantoic	B-Multi-tissue_structure
membrane	I-Multi-tissue_structure
(	O
CAM	B-Multi-tissue_structure
)	O
system	O
.	O

As	O
antagonists	O
were	O
used	O
the	O
tripeptide	O
FPR	O
and	O
non	O
-	O
peptide	O
1	O
,	O
4	O
-	O
disubstituted	O
piperazine	O
derivatives	O
.	O

The	O
pentapeptide	O
SFLLR	O
,	O
like	O
thrombin	O
,	O
caused	O
a	O
marked	O
stimulation	O
of	O
angiogenesis	O
in	O
the	O
CAM	B-Multi-tissue_structure
.	O

FPR	O
and	O
the	O
piperazine	O
derivatives	O
caused	O
suppression	O
of	O
angiogenesis	O
and	O
in	O
combination	O
with	O
thrombin	O
antagonized	O
its	O
angiogenic	O
effect	O
.	O

Thrombin	O
and	O
SFLLR	O
activated	O
progelatinase	O
A	O
(	O
MMP	O
-	O
2	O
)	O
in	O
the	O
culture	O
medium	O
of	O
human	B-Cell
umbilical	I-Cell
cord	I-Cell
endothelial	I-Cell
cells	I-Cell
(	O
HUVECs	B-Cell
)	O
.	O

MMP	O
-	O
2	O
is	O
involved	O
in	O
the	O
early	O
steps	O
of	O
angiogenesis	O
leading	O
to	O
local	O
dissolution	O
of	O
basement	B-Cellular_component
membrane	I-Cellular_component
collagen	O
and	O
migration	O
of	O
the	O
activated	O
endothelial	B-Cell
cells	I-Cell
.	O

FPR	O
and	O
the	O
piperazine	O
derivatives	O
inhibited	O
the	O
activation	O
of	O
this	O
enzyme	O
.	O

They	O
also	O
antagonised	O
the	O
effects	O
of	O
both	O
thrombin	O
and	O
SFLLR	O
on	O
MMP	O
-	O
2	O
activation	O
.	O

These	O
results	O
suggest	O
that	O
non	O
-	O
thrombogenic	O
agonists	O
or	O
antagonists	O
of	O
the	O
activated	O
thrombin	O
receptor	O
can	O
be	O
used	O
as	O
modulators	O
of	O
angiogenesis	O
.	O

